Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: A prospective analysis of data from pharmacy claims
| Autor: | Colleen A. McHorney, Charles M. Alexander, Jeffrey B. Simmons, C. Victor Spain |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Predictive validity medicine.medical_specialty Databases Factual Pharmacy Drug Prescriptions Insurance Claim Review Sex Factors Internal medicine Diabetes mellitus Statistics medicine Humans Pharmacology (medical) Prospective Studies Medical prescription Prospective cohort study Selection Bias Aged Asthma Pharmacies Pharmacology business.industry Age Factors Reproducibility of Results Middle Aged medicine.disease Health Surveys Massachusetts Socioeconomic Factors Sample size determination Sample Size Chronic Disease Patient Compliance Female business Algorithms Dyslipidemia Forecasting |
| Zdroj: | Clinical Therapeutics. 31:2584-2607 |
| ISSN: | 0149-2918 |
| DOI: | 10.1016/j.clinthera.2009.11.030 |
| Popis: | Objective: The aim of this article was to assess the predictive validity of the Adherence Estimator—a 3-item instrument designed to estimate a patient’s propensity to adhere to medications prescribed for chronic disease. Methods: The Adherence Estimator was a 3-item part of a larger survey mailed to adults aged ≥40 years who had a qualifying index prescription filled in June 2008. A qualifying prescription was defined as one for a medication indicated for the treatment of 1 of 5 chronic diseases (cardiovascular disease, dyslipidemia [lipidlowering drugs], diabetes [oral antihyperglycemics], osteoporosis [oral bisphosphonates], or asthma). Outcomes were compared between the adherence risk groups derived from the Adherence Estimator (low risk = score of 0, medium risk = score of 2–7, and high risk = score of 8–36). Treatment persistence over a period of 9 months was measured using pharmacy claims data. The primary outcome was the median proportion of days covered (PDC) by ≥1 medication during the first 9 months after the index fill. Secondary outcomes included adherence to the index medication, defined as PDC dichotomized to ≥0.80 or |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect